A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes

This multicenter, randomized, controlled trial evaluated the efficacy and safety of automated insulin delivery (AID) in adults with insulin treated type 2 diabetes. Participants were assigned in a 2:1 ratio to receive AID (n=215) or continue their pretrial insulin delivery method with continuous glucose monitoring (CGM; n=104). At 13 weeks, the AID group showed a significant reduction in glycated hemoglobin levels (mean adjusted difference: 0.6 percentage points; 95% CI, 0.8 to 0.4; P<0.001) and increased time in the target glucose range (70–180 mg/dL; mean difference: 14 percentage points; 95% CI, 11 to 17; P<0.001) compared to the control group. Hypoglycemia frequency was low in both groups. The study demonstrates that AID safely improves glycemic control in type 2 diabetes without increasing hypoglycemia.

This multicenter, randomized, controlled trial evaluated the efficacy and safety of automated insulin delivery (AID) in adults with insulin treated type 2 diabetes. Participants were assigned in a 2:1 ratio to receive AID (n=215) or continue their pretrial insulin delivery method with continuous glucose monitoring (CGM; n=104). At 13 weeks, the AID group showed a significant reduction in glycated hemoglobin levels (mean adjusted difference: 0.6 percentage points; 95% CI, 0.8 to 0.4; P<0.001) and increased time in the target glucose range (70–180 mg/dL; mean difference: 14 percentage points; 95% CI, 11 to 17; P<0.001) compared to the control group. Hypoglycemia frequency was low in both groups. The study demonstrates that AID safely improves glycemic control in type 2 diabetes without increasing hypoglycemia.